The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

In recent years, the therapeutic landscape for hematological malignancies has undergone a profound transformation, driven by ...

To address this challenge, CTMC has established a patient material bank, enabling early-stage process development with clinically relevant samples. This resource also supports continuous process ...

Relative survival increased from 64% to 66%, overall survival from 54% to 55%, and lymphoma-specific survival from 64% to 66%.

An ICMR-funded trial led by CMC Vellore demonstrated that CAR-T therapy, which uses a patient’s own T cells to fight cancer, can be safely manufactured at the hospital and infused to treat patients in ...

Biomedical engineers at Georgia Tech created a treatment that could one day unlock a universal strategy for treating some of ...

Cancer patients living in southern Utah and nearby states now have a facility offering a highly specialized treatment much closer to home.

In separate live virtual events, Sarah A. Holstein, MD, PhD, and Shashank Cingam, MD, discuss options for a patient with relapsed/refractory multiple myeloma and the use of chimeric antigen receptor ...

Yescarta – a CD19-directed genetically modified autologous T-cell immunotherapy investigated in the ZUMA-1 trial – is the first chimeric antigen receptor (CAR) T-cell therapy recommended for ...

Personalized medicine is already a reality in clinical practice, and CAR-T cell therapy is one of its most promising tools.